Last reviewed · How we verify

NCT03931798: VST

The Visual Scanning Test: a Neuropsychological Tool to Assess Extrapersonal Visual Unilateral Spatial Neglect

Completed NA Last updated 7 May 2019
What this trial tests

NA trial testing Visual Scanning Test in Spatial Neglect in 86 participants. Completed in 9 January 2018.

Timeline
2 November 2015
Primary endpoint
15 January 2017
9 January 2018

Quick facts

Lead sponsorFondazione Don Carlo Gnocchi Onlus
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment86
Start date2 November 2015
Primary completion15 January 2017
Estimated completion9 January 2018

Drugs / interventions tested

Conditions studied

Sponsor

Fondazione Don Carlo Gnocchi Onlus — full company profile →

Who can join

18 and older, any sex, with Spatial Neglect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Presentation and standardization on a normative sample of a new neuropsychological tool to provide a quantitative assessment of visual unilateral spatial neglect in the extrapersonal portion of space.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The Visual Scanning Test: a newly developed neuropsychological tool to assess and target rehabilitation of extrapersonal visual unilateral spatial neglect.
    Borsotti M, Mosca IE, Di Lauro F, Pancani S, et al · · 2020 · cited 3× · PMID 31897939 · DOI 10.1007/s10072-019-04218-2

Verify or expand the search:

Other recruiting trials for Spatial Neglect

Currently open trials in the same condition.

Other Fondazione Don Carlo Gnocchi Onlus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03931798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing